Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5363 + Olaparib + Durvalumab in Advanced Solid Tumors
NCT03772561Phase 1Recruiting
- Sponsor
- National University Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in solid tumor, sponsored by National University Hospital. Primary endpoints: Safety and Tolerability, Maximum Tolerated Dose and 2 more. Started Dec 2018; status: recruiting.
02
Drugs
capivasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03772561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772561.